TickerGuard
Buy Day today: Neutral (57) Mixed market breadth · no major macro event
QURE

Uniqure NV

Healthcare · Biotechnology

22.60$ +0.2% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Balance Sheet

All figures as a percentage of total assets in the same period.

Tick rows to compare them in a chart (up to 4)

Balance Sheet QURE
Line item 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
81.5% 37.6% 19.8% 71.0% 59.9% 86.5% 75.7% 77.9% 86.4% 85.6% 76.1% 77.6% 67.6% 78.4% 70.1% 79.5%
78.7% 19.0% 4.7% 61.1% 55.6% 84.1% 69.6% 76.3% 85.8% 84.2% 72.0% 68.7% 32.3% 29.0% 28.6% 9.7%
78.7% 19.0% 4.7% 61.1% 55.6% 84.1% 69.6% 76.3% 85.8% 84.2% 72.0% 68.7% 50.1% 74.3% 66.0% 75.5%
2.8% 18.7% 15.1% 6.6% 3.6% 1.6% 4.8% 0.8% 0.1% 0.2% 1.9% 7.3% 14.5% 0.5% 1.1% 0.7%
0.0% – -15.1% 2.2% 0.2% 0.2% 0.5% 0.5% 0.4% 1.1% 1.3% 1.3% 1.0% 1.4% 0.0% –
– – 21.2% 6.7% 20.4% 9.8% 18.8% 16.4% 10.7% 6.4% 9.5% 5.4% 11.8% – – –
– – – – 1.4% 0.2% 0.2% 0.3% 0.2% 0.1% 0.2% 3.4% 3.6% 3.2% 4.0% 3.1%
12.8% 47.0% 58.9% 20.0% 17.1% 3.0% 4.4% 4.2% 1.9% 1.2% 1.0% 7.7% 8.3% 7.3% 12.8% 8.8%
39.8% 144.7% 108.0% 85.7% 55.0% 50.6% 66.6% 56.9% 34.4% 28.0% 28.3% 26.4% 32.5% 75.0% 101.2% 75.9%
18.5% 63.3% 100.0% 26.8% 12.8% 10.1% 11.9% 9.2% 7.3% 7.1% 8.0% 4.5% 10.8% 8.9% 7.2% 7.6%
– – – 2.2% 0.7% 2.1% 0.3% 0.9% 2.9% 1.3% 1.6% 0.7% 1.2% 1.0% 0.6% 0.5%
6.9% 29.9% 10.3% 9.0% 3.4% 1.5% 2.9% 1.4% 1.4% 1.3% 1.1% 0.3% 1.6% 0.8% 1.3% 0.6%
– – 8.1% 16.9% 17.2% 5.5% 10.3% 9.5% 13.0% 8.0% 10.5% 12.5% 14.6% 12.2% 9.2% 6.0%
60.2% -44.7% -8.0% 14.3% 45.0% 49.4% 33.4% 43.1% 65.6% 72.0% 71.7% 73.6% 67.5% 25.0% -1.2% 24.1%
-388.5% -1,817.8% -2,105.9% -369.6% -189.0% -104.3% -208.2% -223.6% -195.5% -147.0% -230.5% -56.2% -82.5% -107.1% -203.0% -161.1%
– 233.9% 239.0% 32.7% 14.7% 8.3% 13.2% 12.9% 13.0% 8.9% 13.1% 5.8% 6.6% 5.7% 8.7% 7.0%

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?